Bi/ond and Ó£ÌÒÊÓƵ collaboration offers a significant advancement for DMD research and drug discovery.
Bi/ond and Ó£ÌÒÊÓƵ collaboration offers a significant advancement for DMD research and drug discovery.
Bi/ond and Ó£ÌÒÊÓƵ collaboration offers a significant advancement for DMD research and drug discovery.
Bi/ond and Ó£ÌÒÊÓƵ collaboration offers a significant advancement for DMD research and drug discovery.
Ó£ÌÒÊÓƵ will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and Ó£ÌÒÊÓƵ Founde...
Ó£ÌÒÊÓƵ featured as one of Europe's fastest-growing startups in Sifted.
Ó£ÌÒÊÓƵ selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.
Ó£ÌÒÊÓƵ's CEO, envisions a new era of cell therapies, where cells themselves become intelligent drugs, precisely tailored to indiv...
Ó£ÌÒÊÓƵ announce first project in multi-year collaboration agreement with The Michael J. Fox Foundation to generate products for r...
Ó£ÌÒÊÓƵ's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
Ginkgo Technology Network brings together over 25 partners across an array of capabilities including AI, genetic medicines, biolog...
Editor-in-Chief Carlos-Filipe Pereira interviews our CEO for the Reprogramming Stars series in the journal Cellular Reprogramming.